血浆Ki67联合miRNA-26b检测诊断肝细胞癌价值分析

doi:10.3969/j.issn.1672-5069.2021.02.029

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (2): 264-267.doi: 10.3969/j.issn.1672-5069.2021.02.029

血浆Ki67联合miRNA-26b检测诊断肝细胞癌价值分析

王若宇, 伍玉南, 唐丹

410007 长沙市湖南中医药大学第一附属医院肝病科(王若宇,伍玉南);
研究生院(唐丹)

收稿日期:2020-03-05 出版日期:2021-03-10 发布日期:2021-04-30
通讯作者: 伍玉南,E-mail:512528756@qq.com
作者简介:王若宇,男,33岁,医学硕士,主治医师。主要从事中西医结合防治肝病研究。E-mail:wry6523@163.com
基金资助:
湖南省自然科学基金资助项目(编号:2019JJ50469)

Diagnostic value of plasma Ki67 and miRNA-26b levels in patients with hepatocellular carcinoma

Wang Ruoyu, Wu Yunan, Tang Dan

Department of Liver Diseases, First Affiliated Hospital, Hunan University of Traditional Chinese Medicine, Changsha 410007, Hunan Province, China

Received:2020-03-05 Online:2021-03-10 Published:2021-04-30

摘要/Abstract

摘要： 目的探讨肝细胞癌(HCC)患者血浆Ki67和miRNA-26b水平变化,分析其诊断效能。方法我院收治的HCC患者90例和乙型肝炎肝硬化患者60例,采用RT-qPCR检测血浆Ki67和miRNA-26b水平,采用ROC曲线分析血浆Ki67和miRNA-26b水平诊断HCC的效能。结果 HCC患者血浆Ki67水平为【1.6(1.1～2.2)】,显著高于肝硬化组【0.4(0.1～1.2),P＜0.05】;HCC患者血浆miRNA-26b水平为【0.7(0.3～1.4)】,显著低于肝硬化组【2.0(1.4～3.0),P＜0.05】;不同肿瘤Edmonson分级、早期是否复发和肿瘤转移患者血浆Ki67和miRNA-26b水平分布差异具有统计学意义(P＜0.05);血浆Ki67诊断HCC的ROC曲线下面积为0.8(95%置信区间为0.7～0.9),血浆miRNA-26b诊断HCC的ROC曲线下面积为0.8(95%置信区间为0.8～0.9)。ROC曲线结果显示,血浆Ki67和miRNA-26b水平诊断HCC的灵敏度分别为55.6%和70.0%,特异度分别为95.0%和83.3%,血浆Ki67和miRNA-26b串联试验诊断的特异度为96.7%,并联试验的灵敏性为87.8%,两指标联合诊断HCC的准确性为85.3%,显著高于单个指标的71.3%和75.3%。结论联合检测血浆Ki67和miRNA-26b水平可帮助诊断HCC,值得临床进一步探讨。

关键词: 肝细胞癌, Ki67, miRNA-26b, 诊断

Abstract: Objective The aim of this study was to investigate the diagnostic efficacy of plasma Ki67 and miRNA-26b levels in patients with hepatocellular carcinoma (HCC).Methods 90 patients with HCC and 60 patients with hepatitis B liver cirrhosis (LC) were admitted to our hospital, and plasma Ki67 and miRNA-26b were detected by RT-qPCR. The ROC curve was applied to analyze the diagnostic efficiency of plasma Ki67 and miRNA-26b levels in patients with HCC.Results The plasma Ki67 level in patients with HCC was 【1.6(1.1-2.2)】, significantly higher than 【0.4(0.1-1.2), P＜0.05】 in patients with LC; plasma miRNA-26b level in patients with HCC was 【0.7(0.3-1.4)】, significantly lower than 【2.0(1.4-3.0), P＜0.05】 in patients with LC; plasma Ki67 and miRNA-26b level distribution in patients with different Edmonson class, early or not relapse and metastasis were significantly different (P＜0.05); The AUC of plasma Ki67 in diagnosing HCC was 0.8(95% CI :0.7-0.9), and that of plasma miRNA-26b was 0.8(95% CI:0.8-0.9).The sensitivities (Se) of plasma Ki67 and miRNA-26b for diagnosing HCC were 55.6% and 70.0%, the specificities (Sp) were 95.0% and 83.3%, and the parallel test of plasma Ki67 and miRNA-26b improved the Sp to 96.7% and the concurrent test improved the Se to 87.8%. The combination the two parameters elevated the accuracy to 85.3%, superior to 71.3% and 75.3% by any one alone.Conclusion The detection of plasma Ki67 and miRNA-26b levels might provide new parameters for the diagnosis of patients with HCC, which warrants further investigation.

Key words: Hepatocellular carcinoma, Ki67, miRNA-26b, Diagnosis

王若宇, 伍玉南, 唐丹. 血浆Ki67联合miRNA-26b检测诊断肝细胞癌价值分析[J]. 实用肝脏病杂志, 2021, 24(2): 264-267.

Wang Ruoyu, Wu Yunan, Tang Dan. Diagnostic value of plasma Ki67 and miRNA-26b levels in patients with hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2021, 24(2): 264-267.

参考文献

[1] Zhang WJ, Jin KP, Wang F, et al. Differences in the prognostic value of tumor size on hepatocellular cancer-specific survival stratified by gender in a SEER population-based study. United Eur Gastroenterol J, 2019, 7(7):933-941.
[2] 郭飞宇, 杨军, 熊书名, 等. 耐药基因蛋白和Ki67在原发性肝癌中的水平及其在预后中的价值. 中华肝脏外科手术学电子杂志, 2018, 7(1):77-81.
[3] Ishimoto T, Baba H, Izumi D, et al. Current perspectives toward the identification of key players in gastric cancer microRNA dysregulation. Int J Cancer, 2016, 138(6):1337-1349.
[4] Jiang LP, Zhu ZT, He CY. Expression of miRNA-26b in the diagnosis and prognosis of patients with non-small-cell lung cancer. Future Oncol, 2016, 12(9):1105-1115.
[5] 中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝胆外科杂志, 2015, 21(3):145-151.
[6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[7] Goh BK, Chow PK, Teo JY, et al. Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma. J Gastrointest Surg, 2014, 18(8):1477-1475.
[8] Berretta M, Cavaliere C, Alessandrini L, et al. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget, 2017, 8(8):14192-14220.
[9] 赵西太, 聂青和. 循环microRNA早期诊断肝细胞癌研究现状及方法学探讨. 实用肝脏病杂志, 2019, 22(2):297-300.
[10] Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch, 2018, 472(3):341-349.
[11] Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology, 2017, 49(2):166-171.
[12] Cuylen S, Blaukopf C, Politi A Z, et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature, 2016, 535(7611):308-312.
[13] Sobecki M, Mrouj K, Camasses A, et al. The cell proliferation antigen Ki-67 organises heterochromatin. eLife, 2016, 5:1-33.
[14] 张小舟, 帅领, 王庆大, 等. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析. 实用肝脏病杂志, 2019, 22(2):268-271.
[15] AlKafaji G, AlMahroos G, Alsayed NA, et al. Peripheral blood microRNA-15a is potential biomarker for type 2 diabetes mellitus and pre-diabetes. Mol Med Rep, 2015, 12(5):7485-7490.
[16] Lin CZ, Ou RW, Hu YH. Lentiviral-mediated microRNA-26b up-regulation inhibits proliferation and migration of hepatocellular carcinoma cells. Kaohsiung J Med Sci, 2018, 34(10):547-555.
[17] Tsai MM, Huang HW, Wang CS, et al. MicroRNA-26b inhibits tumor metastasis by targeting the KPNA2/c-jun pathway in human gastric cance. Oncotarget,2016, 7(26):39511-39526.
[18] Zheng WD, Zhou FL, Lin N. MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression.Genet Mol Res, 2015, 14(4):16872-16879.
[19] Xia M, Duan ML, Tong JH, et al. MiR-26b suppresses tumor cell proliferation, migration and invasion by directly targeting COX-2 in lung cancer.Eur Rev Med Pharmacol Sci, 2015, 19(24):4728-4737.
[20] Benderska N, Dittrich A L, Knaup S, et al. miRNA-26b overexpression in ulcerative colitis-associated carcinogenesis.Inflamm Bowel Dis, 2015, 21(9):2039-2051.

血浆Ki67联合miRNA-26b检测诊断肝细胞癌价值分析

Diagnostic value of plasma Ki67 and miRNA-26b levels in patients with hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	贾群玲, 徐志宾, 韩舒. 非酒精性脂肪性肝病患者磁共振质子密度脂肪分数变化[J]. 实用肝脏病杂志, 2021, 24(3): 359-362.
[2]	刘彦荣, 王苗, 曾果, 许晓亮. MRI弥散加权成像对原发性硬化性胆管炎患者肝纤维化评估价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 375-378.
[3]	南东, 洪金玲, 姜海宇. 应用DCE-MRI技术评估乙型肝炎肝硬化患者食管胃底静脉曲张严重程度的效能分析[J]. 实用肝脏病杂志, 2021, 24(3): 407-410.
[4]	王耀政, 王瑜琳, 林毅. F-FDG PET/CT诊断胆管细胞癌分期价值研究[J]. 实用肝脏病杂志, 2021, 24(3): 427-430.
[5]	干艳英, 钟凯, 官燕玲, 李慧敏. 三种影像学方法诊断肝外胆管结石比较研究[J]. 实用肝脏病杂志, 2021, 24(3): 439-442.
[6]	韩文有, 李向军, 赵森峰, 徐俊梅, 刘博. 术前胆汁CT值测定诊断胆囊泥沙样结石的应用价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 443-446.
[7]	朱琳, 秦刚. 妊娠特有肝病诊治进展[J]. 实用肝脏病杂志, 2021, 24(3): 449-452.
[8]	白洁, 郑素军. 重视和推进对遗传代谢性肝病的认识和研究[J]. 实用肝脏病杂志, 2021, 24(2): 153-155.
[9]	张思薇, 孔银, 刘天府, 刘元元, 麻爱娣, 李永芳, 李娟, 张岭漪. 肝脏硬度检测联合吲哚菁绿滞留率测定对血清转氨酶正常或轻度升高的慢性乙型肝炎患者肝组织学病变进展的预测价值[J]. 实用肝脏病杂志, 2021, 24(2): 184-187.
[10]	代海峰, 王甜, 雷迅, 蔡佳, 黄文祥. 应用瞬时弹性成像技术联合APRI和AAR指数评估慢性乙型肝炎患者肝纤维化临床价值研究[J]. 实用肝脏病杂志, 2021, 24(2): 196-199.
[11]	杨振辉, 古宝欢, 戴小灵. 非酒精性脂肪性肝炎患者肝脏受控衰减参数的变化[J]. 实用肝脏病杂志, 2021, 24(2): 212-215.
[12]	徐春玲, 苗重昌, 刘雨成, 张雪, 史曙光, 李树芸. 应用MRI多回波水脂分离技术评估代谢相关性脂肪性肝病患者肝脏脂肪含量的临床意义[J]. 实用肝脏病杂志, 2021, 24(2): 220-223.
[13]	陈少华, 吴哲, 魏志鸿, 陈鹏. 肝细胞癌患者血清癌基因和抑癌基因蛋白水平变化[J]. 实用肝脏病杂志, 2021, 24(2): 244-247.
[14]	许超, 王森钰, 罗援烨, 陈王丽, 周芸, 盛以泉, 郭满盈. 肝细胞癌患者PBMCs TLR 2/4表达和小肠细菌过度生长对TACE术后生存期的影响[J]. 实用肝脏病杂志, 2021, 24(2): 248-251.
[15]	李曼, 李静, 陈文玲, 陈永利, 王力军. 体外局部高频热疗联合放疗治疗进展期肝细胞癌患者临床疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 256-259.